Quote
95.55
+0.89 (+0.94%)
We have scored 87 news catalysts on CVS (CVS) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.34). Most of the impact sits in sector healthcare and institutional appeal.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
95.28–96.01
Open
95.44
Prev close
94.66
Volume
4.5M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged CVS or its network in the window yet.
Show more CVS articles →Analysts publish price targets on CVS, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
22 analyst price targets from $103 to $126
as of 2026-09-09
The market is 15% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about CVS — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of CVS, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for CVS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price at $95.55 sits at the very bottom of 22 published models (0th percentile by count), fully endorsing only the HSBC target at $103 and rejecting a wall of 15 bull cases up to $126, meaning the market is paying for current guidance but refuses to credit any further upside.
What the disagreement turns on
Whether CVS can convert its raised 2026 guidance into sustained margin expansion and higher cash flow, rather than using the gains to absorb elevated medical costs — and the wired data can only track unit volumes to see if the top-line growth holds, not the pricing or cost trends that would settle the margin question.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
